secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001171843-25-005116
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q2 net loss $15.9M, cash $122.9M; Phase 2 HBV study dosing imminent
--------------------------------------------------------------------------

- Net loss of $15.9M ($1.53/sh) vs net income of $5.1M ($0.81/sh) in Q2 2024, driven by change in warrant fair value.
- Cash, cash equivalents and investments $122.9M as of June 30, 2025, expected to fund operations into H2 2026.
- Phase 2 B-SUPREME study of ALG-000184 (HBV) starting; interim data expected 2026, topline 2027.
- ALG-055009 (MASH) Phase 2a data presented; company evaluating partnership options for continued development.
- R&D expenses fell to $14.0M from $21.1M YoY due to MASH trial completion, offset by HBV program spend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/0001171843-25-005116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/f8k_080625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer